Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 21, 2025 08:00 ET | Source: GLD Partners, LP

GLD Partners, LP Acquires Seelos Therapeutics, Inc. Assets, Strengthening GLD’s Growing Life Sciences Portfolio

LOS ANGELES, Oct. 21, 2025 (GLOBE NEWSWIRE) -- GLD Partners, LP, with a growing footprint of investments in life sciences, healthcare, and biotech, today announced the successful acquisition of...
October 15, 2025 11:24 ET | Source: HMNC Holding GmbH

Ketabon Presents New Data Showing Antidepressant Effects of Oral Ketamine (KET01) Are Independent of Dissociation

Ketabon, a JV between HMNC and Develco, shared new post hoc Phase 2 data for oral ketamine (KET01) in treatment-resistant depression (TRD)
October 01, 2025 08:00 ET | Source: ATMA CENA

ATMA CENA Grows National Mental Health Network to 13 Clinics

ATMA CENA announce the expansion of its psychedelic therapy clinic network to 13 locations across Canada
September 05, 2025 07:55 ET | Source: Firefly Neuroscience, Inc.

Firefly Neuroscience Partners with HealingMaps to Offer Cognitive Electrophysiology Analytics to Over 2,500 Ketamine, Psilocybin, and TMS Clinics Across North America

KENMORE, N.Y. and MIAMI, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that...
August 14, 2025 08:11 ET | Source: Research and Markets

Psychedelic Drugs Market Research Report 2025-2033 | Rising Demand for Non-Hallucinogenic Psychedelics Expands Patient Base, Breakthrough Regulatory Designations Accelerate Approvals

Dublin, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The "Psychedelic Drugs: Market Share, and Growth Analysis by Product Type (LSD, Psilocybin, MDMA, Ketamine), Application, End User, Technology" has been...
August 11, 2025 09:26 ET | Source: PharmaTher Holdings Ltd.

PharmaTher Announces FDA Approval of Ketamine (KETARx™)

TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the...
July 16, 2025 09:00 ET | Source: Multidisciplinary Association for Psychedelic Studies (MAPS)

Following Psychedelic Science 2025 Success, MAPS Publishes First of Hundreds of Conference Session Videos

Enhanced Virtual Trip platform goes live with improved user experience and first selection of PS2025 session videosConference drew 8,000+ attendees, more than $1 million donated, and 1,100+ recurring...
April 30, 2025 08:11 ET | Source: Silo Pharma, Inc.

Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

— Successfully demonstrates strong tolerability, sustained drug release and safety SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo,” or the “Company”), a...
April 02, 2025 08:00 ET | Source: Brain & Behavior Research Foundation

Developing a Potential New Treatment for Chronic PTSD: Ketamine Combined with Written Exposure Therapy

New York, April 02, 2025 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) invites the public to a free webinar, “Developing a Potential New Treatment for Chronic PTSD:...
February 21, 2025 07:02 ET | Source: Research and Markets

Ketamine Industry Research 2025: Analysis Through 2019-2029 - Market Dynamics, Supply & Demand, Suppliers, Regional Market Overviews

Dublin, Feb. 21, 2025 (GLOBE NEWSWIRE) -- The "Ketamine (CAS 6740-88-1) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ...